Hello,
Welcome to Insider
- How Amazon and Walmart stack up in their latest battleground, healthcare;
- We rounded up the 17 highest-paid drug industry CEOs;
- Morgan Stanley analysts lay out how Amazon could change how benefits are designed.
If you're new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let's get to it...
But first: on Monday evening, the US Food and Drug Administration authorized Pfizer's coronavirus vaccine for 12- to 15-year-olds.
It's the first to be authorized for that age group, expanding its use beyond people 16 and up here in the US.
Kids in that age group could get the shot as soon as Thursday, the FDA said.
Amazon and Walmart are facing off on a new battleground: healthcare
Walmart andAmazon launched their healthcare-delivery businesses within weeks of each other in 2019.- Two years later, Amazon Care has its first client and Walmart Health is buying a telehealth company.
- It's a sign of a troubled, evolving industry in the wake of the coronavirus pandemic.
Here are the 17 highest-paid drug industry CEOs, including 2 execs who brought in $100 million-plus paydays in 2020
- Insider found the highest-paid
CEOs in the drug industry. - We analyzed CEO pay in 2020 at nearly 200 pharma and biotech companies.
Here are the 17 CEOs who made the most>>
Morgan Stanley lays out how Amazon could reshape the way companies provide healthcare
- Amazon's healthcare strategy is moving toward customized benefits, according to Morgan Stanley.
- A new analyst note highlights its focus on employers and data-driven customization for Prime users.
- It also lays out how Amazon could compete with competitors like One Medical and Teladoc.
More stories we're reading:
- The Biden administration reverses Trump and restores antidiscrimination protections for transgender Americans (Insider)
- Novavax isn't expected to seek authorization for its coronavirus vaccine until June (Washington Post)
- Still scared to return to normal life? Maybe you have 'the freeze' like me. (Insider)
- AstraZeneca is weighing skipping emergency authorization in favor of getting its vaccine fully approved - a much longer process (The Wall Street Journal)
- Lydia